ACAD Stock: Price, Earnings History and SEC Filings
Acadia Pharmaceuticals Inc. (ACAD) last traded at $20.59, down 0.82% on the latest session and up 2.2% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.18 against an analyst estimate of $0.06, a beat of 200.0%.
$20.59 -0.82%
1 month+2.18%
52-week high$30.96
52-week low$18.39
Volume1.14M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ACAD earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $0.18 | $0.06 | +200.00% |
| Mar 2026 | May 6, 2026 | $0.02 | $0.04 | -50.00% |
| Dec 2025 | Feb 25, 2026 | $0.16 | $0.12 | +33.33% |
| Sep 2025 | Nov 5, 2025 | $0.26 | $0.14 | +85.71% |
ACAD beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for ACAD
SEC filing data is not available right now. You can search for ACAD on SEC EDGAR.
ACAD news
- Regenxbio (RGNX) Expected to Beat Earnings Estimates: Should You Buy?Oct 29, 2026 · finance.yahoo.com
- Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026Oct 28, 2026 · finance.yahoo.com
- Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to DeclineOct 28, 2026 · finance.yahoo.com
- Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026Oct 21, 2026 · finance.yahoo.com
- Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?Oct 21, 2026 · finance.yahoo.com
About Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc. (ACAD) is a US-listed public company on Nasdaq.